Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $36.00.
A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, October 2nd. TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, November 13th. They issued a "strong-buy" rating on the stock. Royal Bank Of Canada upgraded Lakefront Biotherapeutics American Depositary Shares from a "sector perform" rating to an "outperform" rating and upped their target price for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a "buy" rating in a research report on Wednesday, September 23rd. Finally, Raymond James Financial reiterated a "market perform" rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Thursday, November 12th.
Read Our Latest Stock Report on LKFT
Lakefront Biotherapeutics American Depositary Shares Stock Down 0.9%
Shares of LKFT stock opened at $34.07 on Thursday. Lakefront Biotherapeutics American Depositary Shares has a 12-month low of $25.68 and a 12-month high of $36.24. The company has a market capitalization of $2.25 billion, a PE ratio of -24.16 and a beta of 0.22. The firm has a 50 day moving average price of $30.75 and a two-hundred day moving average price of $29.94.
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $7.87 million for the quarter. As a group, research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post 0.09 EPS for the current year.
Lakefront Biotherapeutics American Depositary Shares declared that its board has authorized a share repurchase plan on Monday, November 16th that allows the company to repurchase $54.95 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 2.5% of its shares through open market purchases. Share repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at about $4,166,000. Alps Advisors Inc. purchased a new stake in Lakefront Biotherapeutics American Depositary Shares during the third quarter worth $2,617,000. Marshall Wace LLP bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at $2,326,000. Entropy Technologies LP bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at $887,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $279,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.
About Lakefront Biotherapeutics American Depositary Shares
(
Get Free Report)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lakefront Biotherapeutics American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lakefront Biotherapeutics American Depositary Shares wasn't on the list.
While Lakefront Biotherapeutics American Depositary Shares currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.